|
US2009082407A1
|
|
Pyridoxamine for the Treatment of Diabetic Kidney Disease
|
|
WO2008013660A2
|
|
Inhibitors of advanced glycation end products
|
|
US2007202111A1
|
|
Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
|
|
US2007065447A1
|
|
Laminin-5 gamma2-binding peptides, related compositions, and use thereof
|
|
WO2005077902A2
|
|
Methods for the synthesis of pyridoxamine
|
|
WO2005052003A2
|
|
Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
|
|
CA2529538A1
|
|
Pyridoxamine for the treatment of diabetic kidney disease
|
|
AU2003268292A1
|
|
Inhibitors of post-amadori advanced glycation end products
|
|
AU4176602A
|
|
Isolated laminin 10
|
|
WO0250111A2
|
|
Isolated laminin 10
|
|
US6955924B2
|
|
Laminin chains: diagnostic uses
|
|
US6638264B1
|
|
Perfusion apparatus and methods for pharmaceutical delivery
|
|
US6703363B1
|
|
Recombinant laminin 5
|
|
AU4678400A
|
|
Laminin 8 and methods for its use
|
|
AU4187200A
|
|
The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
|
|
WO0052023A1
|
|
Method for the detection of congenital nephrotic syndrome
|
|
AU3087799A
|
|
Nephrin gene and protein
|
|
US6576418B1
|
|
Method for determining the nucleotide sequence of the gene for the α5(IV) chain of human type IV collagen
|
